Background {#Sec1}
==========

The maintenance of physiological cell membrane fluidity is a prerequisite associated with normal cell growth and division \[[@CR1]\] and its alterations have been described in various pathologies, such as obesity, diabetes mellitus and different types of cancer \[[@CR1]--[@CR4]\]. Lipid accumulation in the cell is important in promoting tissue inflammation \[[@CR5]\] and this damage is not caused not only by the quantity but also by the quality of accumulated lipids in the cells \[[@CR6]\]. In this contest, lipidomic analysis, as a new technology, allows to identify specific metabolic profiles, typical of a disease, as NAFLD.

The lipidomic profiling of erythrocyte membranes provides exhaustive information on metabolic and nutritional pathways which influence the lipid balance and homeostasis of the organism. Several studies have demonstrated that the analysis of fatty acids composition of circulating erythrocyte membrane can be considered an appropriate biomarker for investigating the relations between the patterns of fatty acid metabolism and specific diseases \[[@CR7], [@CR8]\], considering that changes in fatty acids composition of erythrocyte membranes may be related to illness status.

Previously, we showed the presence of an altered fatty acid profile in erythrocyte membranes of patients with colorectal cancer \[[@CR9]\]. The patients suffered of colorectal cancer showed a lower percentage of total *n*-3-series polyunsaturated fatty acids (n-3-PUFAs) than controls and consequently this finding was reflected in the higher ratio n-6-PUFA/n-3-PUFA observed in patients having cancer compared to controls.

The saturation index (SI) of cell membrane is the ratio of stearic acid to oleic acid and it is considered an indicator of membrane rigidity \[[@CR7]\]. Low levels of SI have been associated to the cell malignant phenotype \[[@CR3]\]. Analysis of fatty acid extracted from leukemic cells and solid tumor tissue showed a significant increase in the oleic acid content respect to stearic acid \[[@CR10], [@CR11]\].In erythrocytes membranes, low levels of SI have been demonstrated to be predictors of postmenopausal breast cancer \[[@CR12]\].

A lipidomic approach has been considered for the detection of the major lipid classes and for the distribution of fatty acids in cell membrane in experimental models of NAFLD and Non-alcoholic Steato-Hepatitis (NASH) \[[@CR5], [@CR13]\]. A modified lipidomic profile has been observed in NAFLD, suggesting that changes in the concentration and quality of lipids in cell membranes might affect the pathogenesis and progression of steatosis or steatohepatitis. Furthermore, NAFLD has been associated with an increase in saturated fatty acids altering the hepatic lipid profile in patients with liver damage \[[@CR5], [@CR6]\].

Therefore, considering that the changes in the concentration and quality of fatty acids play a central role in the development and progression of NAFLD, the present study was designed to analyze the fatty acids profile in red blood cell membranes of patients with NAFLD in order to identify and validate membrane profiles associated with hepatic injury. Moreover, a possible clinical association between specific lipidomic profiles and degree of liver damage will be assessed.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This work is part of NUTRIATT (NUTRItion and AcTiviTy) study, a nutritional trial (registration number: NCT02347696) enrolling consecutive subjects with NAFLD. Diagnosis of NAFLD was performed by using vibration-controlled elastography (VCTE) implemented on FibroScan® (Echosens, Paris, France.) \[[@CR14]\]. NAFLD was categorized as absent (\<215 dB), mild (215--250 dB), moderate (251--299 dB) and severe (≥300 dB) \[[@CR15]\].

Trial inclusion criteria included: Body Mass Index (BMI) ≥ 25, calculated as weight in kilograms divided by the square of the height in meters (kg/m^2^); age \> 30 years old and \<60 years old; NAFLD moderate or severe. Exclusion criteria included: overt cardiovascular disease and revascularization procedures; stroke; clinical peripheral artery disease; current treatment with insulin or oral hypoglycemic drugs; fasting glucose \>126 mg/ dl, or casual glucose \>200 mg/dl; more than 20 g/daily of alcohol intake; severe medical condition that may impair the person to participate in a nutritional intervention study; people following a special diet or involved in a program for weight loss, or who had experienced recent weight loss and inability to follow a diet for religious or other reasons. The assessment of alcohol intake was performed by means of a questionnaire \[[@CR16]\] and a personal interview.

In this study, we present data obtained at baseline from 101 subjects (55 males and 46 females) enrolled consecutively in NUTRIATT study. Participants were fasted for 12 h prior to examination. Blood samples taken from the subjects by venous puncture were collected in tubes containing Ethylenediamine tetraacetic Acid (K-EDTA) anticoagulant.

For in vitro isolation of erythrocytes, blood samples with K-EDTA were quickly layered on a Ficoll-Paque solution and centrifuged at 400×*g* for 40 min at 20 °C. The lymphocytes and plasma were then removed and the erythrocytes were recovered from the bottom layer and washed with 4-volumes of phosphate-buffered saline. Isolated red blood cells were stored at −80 °C until they were assayed. Moreover, aliquots of blood serum were taken from each subject and shipped to the central laboratory for routine analyses. All the analyses were performed within 3 months.

All subjects gave their informed consent to participate in the study.

Fatty acids extraction, purification and preparation of fatty acid methyl esters {#Sec4}
--------------------------------------------------------------------------------

We used the modified method of Moilanen \[[@CR17]\], that is itself a modification of the method described by Folch \[[@CR18]\]. Each sample of red blood cells (RBC) was thawed bringing to room temperature. Fatty acids were hydrolyzed from phospholipids of RBC membranes by adding 0.9 ml of an acidified salt solution (H~2~SO~4~ 2·10^−4^ M, NaCl 0.1%). Afterwards, were added 5.0 ml of chloroform: methanol (2:1, *v*/v) (Sigma-Aldrich, Milan, Italy) and the samples were mixed thoroughly and centrifuged at 1000 × *g* for 10 min. The lower layer, containing fatty acids, was removed with care, replaced in a new tube and dried by a centrifugal evaporator (Bio-Rad, Milan, Italy). Preparation of fatty acid methyl esters (FAME) was carried out by adding 1 ml of toluene and 1.5 ml of BF~3·~MeOH 14% (Sigma-Aldrich, Milan, Italy) and incubating for 2 h at 80 °C. To the samples were added 2.5 ml of 5% aqueous sodium chloride solution, 1.5 ml of toluene and then centrifuged at 470×*g* for 10 min. The upper layer, containing FAME, was collected and transferred into a vial and analyzed.

Gas chromatography and fatty acids quantification {#Sec5}
-------------------------------------------------

Fatty acids quantification was performed by using a gas chromatography equipment with auto-sampler, a split/split less injector, FID detector and a hydrogen gas generator (Thermo Fisher Scientific, Milan, Italy). Separation of FAME was carried out on a BPX 70 capillary column SGE Analytical Science, P/N SGE054623, 60 m × 0.25 mm ID -- BPX70 0.25 UM (SGE Europe Ltd., United Kingdom). Hydrogen was used as carrier gas, 3.0 ml min^−1^, constant flow mode; the amount injected was 1 μl in split less mode (split flow 50 ml min^−1^, split less time 1 min). The temperature of the injector and the FID detector were 250 °C. The initial temperature of the oven was 40 °C, then it increased to 170 °C at 10 °C min^−1^ for 5 min, then to 200 °C at 4 °C min^−1^ for another 5 min and finally the temperature increased to 240 °C at 10 °C min^−1^and held for 5 min.

Quantification of fatty acid methyl esters was performed using a mixture of standards (Supelco 37-Component FAME Mix, Sigma-Aldrich, Milan, Italy).

Statistical analysis {#Sec6}
--------------------

All data were expressed as mean ± SD. ANOVA and Tukey Multiple comparison test were performed to estimate differences among groups. A probabilistic type I error of ≤0.05 was considered as statistically significant.

Multivariate regression analysis was performed to evaluate the role of confounding factors on final results. All analysis were performed by using Stata 14.2 statistical software.

Results {#Sec7}
=======

Table [1](#Tab1){ref-type="table"} shows clinical and biochemical characteristics of subjects at the baseline stratified for degree of NAFLD. We found 24 subjects with absentNAFLD (i.e. control group), 30 with moderate and 47 with severe NAFLD.Table 1Clinical and biochemical variables in controls and patients with NAFLDControls (*n* = 24) mean ± SDModerate NAFLD (*n* = 30) mean ± SDSevere NAFLD (*n* = 47) mean ± SD*P* valueAge50.8 ± 8.450.5 ± 10.650.5 ± 10.60.4BMI30.9 ± 3.230.7 ± 2.932.3 ± 4.90.02 Controls vs SevereAzotemia21.5 ± 21.536.4 ± 10.234.6 ± 9.80.001 Controls vs Moderate and SevereFerritin114.7 ± 148.6137.9 ± 142.2149.4 ± 178.90.42ALT28.9 ± 20.429.2 ± 10.340.7 ± 23.00.02 Controls vs SevereAST21.91 ± 4.1823.53 ± 4.9129.37 ± 10.840.01 Controls vs SevereGGT29.9 ± 46.523.5 ± 12.131.9 ± 28.30.8Total cholesterol198.6 ± 33.3210.6 ± 33.9208.6 ± 35.90.28Cholesterol- HDL51.6 ± 13.248.1 ± 13.741.1 ± 8.30.001 Controls vs SevereTriglycerides100.7 ± 46.5118.7 ± 69.1151.2 ± 89.00.01 Controls vs SevereGlycemia87.4 ± 12.293.2 ± 6.098.8 ± 15.10.001 Controls vs SevereSerum Insulin7.18 ± 3.039.65 ± 3.9613.2 ± 4.80.04 and 0.001 Controls vs Moderate and Severe, respectivelyHOMA index1.59 ± 0.722.22 ± 0.903.16 ± 1.270.04 and 0.001 Controls vs Moderate and Severe, respectivelySFAs52.6 ± 8.852.3 ± 9.653.1 ± 10.90.84MUFAs22.4 ± 5.522.6 ± 6.222.0 ± 7.20.8PUFAs24.9 ± 5.725.0 ± 4.624.8 ± 5.60.9

To probe the consistency and validity of our estimates we performed a post-hoc sample size estimation by taking into account our effect estimates. Type I (α) and II (β) probabilistic errors varied between 0.05 and 0.01 and between 0.20 and 0.05 respectively, so the power of the study varied from 0.80 to 0.95. Sample sizes obtained varied from *n* = 4 (α = 0.05, power 0.80) to *n* = 30 (α = 0.01, power 0.95) and then, the number of samples resulted appropriate.

The values of serum azotemia, ferritin, triglycerides, cholesterol-HDL, glycemia, insulin and HOMA index were significantly higher in the subjects with NAFLD compared to control group. Moreover, stratifying for score of NAFLD, a significant trend from lower to higher degree of NAFLD for these parameters was also detected (Table [1](#Tab1){ref-type="table"}).

Figure [1](#Fig1){ref-type="fig"} shows a representative profile of fatty acids composition of erythrocytes membrane from a subject with severe NAFLD and a subject without liver injury.Fig. 1Chromatogram profile of fatty acids composition of erythrocytes membrane from a control subject and patient with severe NAFLD

A significant decrease of the erythrocyte membrane SI was observed in subjects with severe NAFLD compared to controls, 1.281 ± 0.31 vs 1.5 ± 0.29, (Fig. [2](#Fig2){ref-type="fig"}, *p* = 0.01, ANOVA and Tukey Multiple comparison test). Lowering of SI was essentially due to the increase of oleic acid content detected in these samples.Fig. 2Saturation index (SI) levels (stearic acid/oleic acid ratio) in erythrocytes membranes from controls and patients with moderate and severe NAFLD. Data are expressed as the mean ± SD. *P \<* 0.05, one-way analysis of variance and Tukey's multiple comparison test

On the other hand, compared to controls, the subjects with severe NAFLD showed higher levels of SI n-7, defined as palmitic to palmitoleic acid ratio (Fig. [3](#Fig3){ref-type="fig"}, *p* \< 0.05, ANOVA and Tukey Multiple comparison test). Moreover, the subjects with severe NAFLD reported enhanced levels of elongase activity, showing high levels of vaccenic acid (Fig. [1](#Fig1){ref-type="fig"}), a product derived from palmitoleic acid through the enzymatic activity of elongase 5 (Elovl5), (Fig. [4](#Fig4){ref-type="fig"}, *p*\<0.05, ANOVA and Tukey Multiple comparison test).Fig. 3Saturation index n-7 levels (palmitic acid/palmitoleic acid ratio) in erythrocytes membranes from controls and patients with moderate and severe NAFLD. Data are expressed as the mean ± SD. *P \<* 0.05, one-way analysis of variance and Tukey's multiple comparison test Fig. 4Levels of Elongase 5 (Elovl5) enzymatic activity in erythrocytes membranes from controls and patients with moderate and severe NAFLD. Data are expressed as the mean ± SD. *P \<* 0.05, one-way analysis of variance and Tukey's multiple comparison test

No significant difference, among groups, was observed in fatty acids profile regarding total Saturated Fatty Acids (SFAs), Monounsaturated Fatty Acids (MUFAs) and PUFAs levels.

To evaluate the role of confounding factors on final results, we performed a multivariate regression analysis (Table [2](#Tab2){ref-type="table"}). In the subjects with moderate and severe NAFLD, SI value was confirmed to be significantly lower respect to controls. This findings supports a role of SI as a biomarker of liver damage.Table 2Multivariate Regression Analysis: Effect of NAFLD score on red blood cell lipid profileSFAsMUFAsPUFAsSISI n-7Elovl5(95% C.I.)(95% C.I.)(95% C.I.)(95% C.I.)(95% C.I.)(95% C.I.)Moderate NAFLD−2.070.251.82−0.65\*16.810.64(−8.51,4.37)(−3.92,4.41)(−1.66,5.30)(−1.19,-0.11)(−19.49,53.11)(−5.66,6.94)Severe NAFLD−1.54−0.592.089−0.54\*25.56−0.20(−7.86,4.85)(−4.71,3.52)(−1.34,5.52)(−1.08,-0.01)(−10.26,61.38)(−6.41,6.02)Age (years)0.23−0.17−0.0650.01−0.760.08(−0.06,0.52)(−0.36,0.02)(−0.22,0.09)(−0.02,0.03)(−2.41,0.90)(−0.02,0.37)Gender (Female)15.34−8.20−7.110−0.25−0.403.83(−6.95,37.64)(−22.64,6.22)(−19.15,4.93)(−2.13,1.62)(−126.03,125.24)(−17.98,25.63)(95% C.I.) \* *p* \< 0.05; \^Adjusted for Age, Gender and biochemical markers

Discussion {#Sec8}
==========

The clinical importance of NAFLD is linked to evidence that it might evolve in steatohepatitis, liver cirrhosis and cancer \[[@CR19]\]. In the effort to detect novel and non-invasive biomarkers for diagnosis of NAFLD, this study demonstrates a relationship between alterations of circulating cell membrane lipidomic profile and degree of liver injury. Lower levels of SI in red blood cell membranes, detected in the patients with severe NAFLD, suggest an impairment of circulating cell membrane structure that can reflect modifications that take place in the liver.

It is widely known that in the pathophysiology of NAFLD, an elevated content of lipids in hepatic tissue, is a major cause of liver damage, affecting cell membrane structure \[[@CR20]\].

In this context, we found the SI in red blood cells to be inversely associated with degree of liver damage. This finding, was also confirmed by multivariate regression analysis, supporting a role of SI as a biomarker of liver injury.

Elevated levels of oleic acid in erythrocytes membrane and consequently low levels of SI have been demonstrated in different pathological conditions \[[@CR8], [@CR21]\]. Low levels of SI have been associated with an increased cancer risk \[[@CR3], [@CR8]\], suggesting that the regulation of membrane fluidity is essential for the metabolic functionality of cells. The reduction of membrane rigidity seems to lead to increased cell metabolism and to higher cell proliferation activity, both features of neoplastic cells.

In this study, we showed that the ratio of saturated to unsaturated fatty acids can be a marker of liver damage and indirectly that the maintenance of normal oleic acid content might preserve the fluidity of membranes, a key feature of cell homeostasis.

Several studies have demonstrated that in the pathogenesis of NAFLD, an altered regulation of desaturation and elongation processes of fatty acids are present. High levels palmitic to palmitoleic acid ratio and lower levels of oleic acid to stearic acid ratio, observed in patients with NAFLD, are probably due to an increased chain elongation and to an altered control of desaturase signaling. A key role in these enzymatic processes is played by stearoyl-coenzyme A desa turase 1, an important enzyme of triglycerides biosynthesis, specific lipid class accumulated in livers of subjects with NAFLD \[[@CR22]\].

Low content of palmitoleic acid, detected in red blood cells membranes of the subjects with severe NAFLD, was justified by high levels of elongase 5 (Elovl5) activity. Elevated activity of Elovl5 enzyme leads to a higher transformation rate of palmitoleic acid in vaccenic acid. Regarding C18:1 n-7, likely *cis*- vaccenic acid, a recent study suggested a role for this fatty acid in the development of chronic kidney disease \[[@CR23]\]. Moreover, circulating concentrations of *cis*-vaccenic acid have been demonstrated to be associated with an increased risk of coronary heart disease and cardiac arrest \[[@CR24], [@CR25]\].

Consistently with our data, being NAFLD associated with cardiovascular diseases \[[@CR26]\], high levels of *cis*-vaccenic acid, correlated with higher degree of liver damage detected in this study, confirm the role for specific fatty acids species in the onset of metabolic pathologies.

Conclusions {#Sec9}
===========

We conclude that the lipidomic approach is important in the diagnosis and the staging of NAFLD. Our data, overall, suggest that SI could be used as a biomarker of liver injury in order to assess therapeutic intervention to restore membrane fatty acids profile. Changes in the dynamics of the fatty acid metabolic processes through diet and life style can be beneficial for the patients with this metabolic disease.
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